Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc-T are provided using compounds of the formula IwhereinR1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1R2 is H, —OH, C1-6 alkoxy or Sac 2R3 is H, —OH, C1-6 alkoxy or Sac 3R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkylR5 is H, C1-6 alkyl or C1-6 acylR6 is H, C1-6 alkyl or C1-6 acylSac 1 Sac 2 and Sac 3 are independently selected saccharide moieties andZ is a steroid moietyor a pharmaceutically acceptable salt, ether or ester form thereof.
